Legal NewsRoom
Menu
Menu
LEGAL NEWS
HOT TOPICS
LexisNexis® Legal Newsroom
ACA and Healthcare Reform
Antitrust and Unfair Competition
Banking and Finance
Bankruptcy
California
Climate Change
Constitutional Law and Civil Rights
Consumer Protection & Privacy
Contracts and Commercial Law
Corporate
Criminal Law and Procedure
Energy
Environmental
Estate and Elder Law
Family Law
Financial Fraud Law
Florida
Fracking and Alternative Energy
Health Care
Hot Topics
Hurricane Sandy
Illinois
Immigration Law
Immigration Reform
Insurance Law
Intellectual Property
International Law
International Trade
Labor and Employment Law
Law360
Legal Business
Lexis® Hub
Litigation
Mealeys
Media and Entertainment
Mergers and Acquisitions
New Jersey
New York
Pennsylvania
Public Contracts
Public media
Public Policy
Real Estate Law
Securities
Sports Law
Tax Law
Technology
Texas
Top Emerging Trends
Torts
Virtual Currency
Workers' Compensation
NEWS & INSIGHT
Blogs and Newsletters
BIZ Blog
Blog Mosaic
Business of Law Blog
Corporate Law Advisory
Legal Content Insider
LexTalk
State Net
®
Capitol Journal
News & Trending Topics
Law360
Legal Insights & Trends
Lexis Practice Advisor Journal
Professional Communities
Business Insight Solutions – Partner Portal
Corporate InfoPro (Corporate Information Professionals)
InfoPro (Legal Information Professionals)
LexisNexis
®
for Developers
Litigators Verdict & Settlement Exchange
VISIT LEXISNEXIS LEGAL & PROFESSIONAL
Search
Search
Please enter a Keyword
This should not be used for legal research but instead can be used to find solutions that will help you do legal research.
Sign In
Browse By Tags
11th Circuit U.S. Court of Appeals
antipsychotic drug
anti-psychotic drug
AstraZeneca
AstraZeneca Pharmaceuticals
Daubert
Daubert v. Merrill Dow Pharmaceuticals
diabetes
drugs
emerging drugs & devices
expert admissibility
J.B. Van Hollen
Johnson &
lawsuit
Liknda Guinn
Linda Guinn v. AstraZeneca Pharmaceuticals LP
Litigation
New Jersey
New Jersey Attorney General
off-label use
personal injury
Risperdal
settle
torts
Zyprexa
LexisNexis Litigation Resource Community Staff
over 12 years ago
Litigation
News Headlines
Wisconsin To Get $4 Million In Multistate Drug Lawsuit
MADISON Wis. – (AP) Attorney General J.B. Van Hollen said Tuesday that Wisconsin will get more than $4 million in a multistate settlement with drug manufacturer AstraZeneca. The drug maker allegedly marketed the anti-psychotic drug Seroquel for...
LexisNexis Litigation Resource Community Staff
over 12 years ago
Litigation
News Headlines
AstraZeneca Pays $198M To Settle Seroquel Lawsuits
LONDON - (AP) AstraZeneca PLC says it has paid around $198 million to settle U.S. lawsuits over its antipsychotic drug Seroquel. Full version available to lexis.com subscriber .
LexisNexis Litigation Resource Community Staff
over 12 years ago
Litigation
News Headlines
AstraZeneca Paying $68.5 Million In Seroquel Settlement
WASHINGTON, D.C. - (AP) AstraZeneca will pay $68.5 million as part of a multistate settlement over allegations that the drug developer promoted its blockbuster psychiatric drug Seroquel for insomnia, Alzheimer's and other unapproved uses. The New...
Tom Moylan
over 12 years ago
Top Emerging Trends
Emerging Issues Law Blog
Plaintiff Expert Excluded by Eleventh Circuit in First Seroquel MDL Bellwether
ATLANTA - (Mealey's) The sole causation expert for the first bellwether plaintiff in the Seroquel multidistrict litigation failed to rule out other causes of weight gain and diabetes, a panel of the 11th Circuit U.S. Court of Appeals said April 7...
Tom Moylan
over 12 years ago
Litigation
Litigation Blog
AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic
TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical...
Tom Moylan
over 12 years ago
Litigation
Litigation Blog
AstraZeneca Settles Nearly 4,000 Seroquel Injury Claims; Terms Confidential
LONDON - (Mealey's) AstraZeneca PLC said July 29 that it has agreed in principle to settle with nearly 4,000 Seroquel product liability plaintiffs. The company said settlement terms are confidential. In notes to its second-quarter financial...
Tom Moylan
over 12 years ago
Litigation
Litigation Blog
11th Circuit Affirms Exclusion Of Plaintiff Expert In First Seroquel Bellwether
ATLANTA — (Mealey’s) The sole causation expert for the first bellwether plaintiff in the Seroquel multidistrict litigation failed to rule out other causes of weight gain and diabetes, a panel of the 11th Circuit U.S. Court of Appeals said...
Tom Moylan
over 11 years ago
Litigation
Litigation Blog
N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the...
Tom Moylan
over 12 years ago
Litigation
Litigation Blog
AstraZeneca Agrees To Settle 17,500 Seroquel Cases For $198 Million
WILMINGTON, Del. — AstraZeneca announced Aug. 9 that it has reached agreements in principle to settle about 17,500 Seroquel claims in the United States for about $198 million. “The specific terms of the agreements, which are the result...